EMEA-001943-PIP05-21

Table of contents

Key facts

Invented name
Ultomiris
Active substance
ravulizumab
Therapeutic area
Neurology
Decision number
P/0413/2021
PIP number
EMEA-001943-PIP05-21
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of amyotrophic lateral sclerosis
Route(s) of administration
Intravenous use
Contact for public enquiries
Alexion Europe SAS

E-mail: pip.enquiries.eu@alexion.com
Tel. +33 147100619

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

Related content

How useful was this page?

Add your rating